Halozyme Therapeutics, Inc. provides earnings guidance for the year 2024. For the period, the company expects Total revenue of $915 million to $985 million, representing growth of 10% to 19% over 2023 total revenue primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED. Revenue from royalties of $500 million to $525 million, representing growth of 12% to 17% over 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.91 USD | +0.23% | +3.47% | +7.98% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.98% | 5.07B | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024